Clinical trial
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, First-in-Human Study Evaluating Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Orally Administered BMS-986521 in Healthy Adult Participants
NCT07283263 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Placebo-Controlled, Double-Blind, First-in-Human Study Evaluating Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Orally Administered BMS-986521 in Healthy Adult Participants
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- December 23, 2025
- Completion date
- November 17, 2026
- Enrollment
- 106 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy volunteers